A bifurcation lesion is a coronary artery disorder, which involves narrowing occurring adjacent to and/or at the origin of an important side branch. Aging and sedentary lifestyle are leading to greater risks of cardiovascular disorders and thereby, bifurcation lesions. Technological advancements and ongoing clinical trials on devices are paving way for novel balloons and stents. Generally, stent implantation is preferred over balloon angioplasty for treatment of the disorder.
Coronary Vascular Lesions to Maintain Dominance through 2025
Stents and balloons can be used for the treatment of coronary vascular and peripheral vascular lesions. Coronary vascular will continue to command the leading share through 2025. Availability of dedicated devices for coronary bifurcation lesions and rise in number of percutaneous coronary intervention procedures performed every year are contributing to the growth of the segment. Increasing clinical trials and advent of novel products are anticipated to supplement the growth of the segment.
The peripheral vascular segment will progress at a higher growth rate through the same period. Rising occurrence of peripheral arterial diseases (PAD) and increasing awareness regarding their treatment can positively impact the growth of the segment. According to a study by the National Institutes of Health (NIH), one in every 20 Americans above 50 years of age is suffering from PAD. Widening application of available products for bifurcation lesions can also drive the growth of the segment.
Market Insights
As per the findings of Grand View Research Inc., the global bifurcation lesions market is projected to expand at a CAGR of 5.6% from 2017 to 2025. Approval of advanced stents is expected to provide an upthrust to the market. For instance, in March 2017, Tryton Side Branch Stent, a product by Tryton Medical, received approval from the US Food and Drug Administration (FDA), which made it the first such device available in U.S. Advancements in imaging modalities, along with an increase in number of skilled surgeons, can augment the market. North America will hold a prominent position throughout the review period (2014–2025), thanks to commercialization of innovative devices for bifurcation lesions.
Some of the prominent companies operating in the market are Boston Scientific Corporation; Johnson & Johnson Services, Inc.; Abbott; Terumo Medical Corporation; and Medtronic.
In-Depth Research Report On Bifurcation Lesions Market:
https://www.grandviewresearch.com/industry-analysis/bifurcation-lesions-market
No comments:
Post a Comment